EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Topical Astaxanthin Attenuates Imiquimod-Induced Psoriasiform Dermatitis by Downregulating Psoriasis-Associated Keratin Gene Expression (Krt16, Krt17, Krt6a) and Inhibiting the JAK-STAT Signaling Pathway

Waleed Khaled Younis Albahadly, Haider Falih Shamikh Al-Saedi, Jamal Ali Ashoor iD, Mohammed Ibrahim Rasool iD, Samer Ali Hasan, Meeqaat H ALtrufi

Molecules · 2026

DOI: 10.3390/molecules31071191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2026. Verfasst von Waleed Khaled Younis Albahadly und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, College of Pharmacy, University of Karbala, Karbala 56001, Iraq. Hauptthemen laut MEDLINE: Imiquimod, Psoriasis, Keratins, Dermatitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriasis is a chronic immune-mediated inflammatory skin disorder characterized by excessive keratinocyte proliferation, oxidative stress, and dysregulated cytokine signaling. Although topical corticosteroids remain the first-line therapy, their long-term use is often limited by adverse effects, highlighting the need for safer non-steroidal therapeutic alternatives. This study investigated the therapeutic efficacy and underlying mechanisms of a topical astaxanthin (AST) formulation in an imiquimod (IMQ)-induced mouse model of psoriasiform dermatitis. Following IMQ induction, mice were randomly assigned to vehicle, clobetasol, or AST treatment groups (0.5–1.5%) for 14 days. Disease progression was evaluated through biochemical analysis of oxidative stress biomarkers, including NADPH oxidase (NOX), malondialdehyde (MDA), nitric oxide (NO), and superoxide dismutase (SOD), as well as ELISA-based quantification of inflammatory cytokines (TNF-α, IL-6, IL-17, and IL-23). Histopathological changes were assessed using hematoxylin and eosin staining, while molecular alterations were examined by RT-qPCR analysis of psoriasis-associated keratin genes (Krt16, Krt17, and Krt6a) and evaluation of JAK–STAT signaling activity. AST treatment significantly suppressed the IL-23/IL-17 inflammatory axis, reduced NOX activity and lipid peroxidation, restored endogenous antioxidant defenses, and inhibited JAK–STAT signaling. These biochemical and molecular effects were accompanied by marked downregulation of keratin gene expression and substantial histological improvement, including normalization of epidermal thickness, reduced parakeratosis, and decreased inflammatory infiltration. Notably, high-dose AST demonstrated therapeutic efficacy comparable to, and in some parameters exceeding, that of clobetasol. Collectively, these findings indicate that topical astaxanthin exerts coordinated antioxidant, anti-inflammatory, and anti-proliferative effects, supporting its potential as a promising multi-target non-steroidal therapeutic candidate for psoriasis management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImiquimodPsoriasisKeratinsDermatitisAnimalsXanthophyllsMiceSignal TransductionOxidative StressJanus KinasesSTAT Transcription FactorsAdministration, TopicalDisease Models, AnimalKeratin-16Down-RegulationCytokinesGene Expression RegulationKeratin-17

Stichwörter der Autor:innen

IL-23/IL-17 axisJAK–STAT signalingantioxidantsastaxanthinimiquimodinflammationkeratinocyte proliferationoxidative stresspsoriasistopical therapy

Substanzen

XanthophyllsImiquimodastaxanthineJanus KinasesSTAT Transcription FactorsKeratinsKeratin-16CytokinesKeratin-17

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, College of Pharmacy, University of Karbala, Karbala 56001, Iraq.
  • Department of Pharmacology and Toxicology, College of Pharmacy, University of Al-Ameed, Karbala 56001, Iraq.
  • Department of Pharmaceutics, College of Pharmacy, University of Karbala, Karbala 56001, Iraq.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Kufa, Najaf 54001, Iraq.

ORCID-Profile: Jamal Ali Ashoor, Mohammed Ibrahim Rasool

Zitieren

APA

Albahadly, W. K. Y., Al-Saedi, H. F. S., Ashoor, J. A., Rasool, M. I., Hasan, S. A., & ALtrufi, M. H. (2026). Topical Astaxanthin Attenuates Imiquimod-Induced Psoriasiform Dermatitis by Downregulating Psoriasis-Associated Keratin Gene Expression (Krt16, Krt17, Krt6a) and Inhibiting the JAK-STAT Signaling Pathway. Molecules. https://doi.org/10.3390/molecules31071191

Vancouver

Albahadly WKY, Al-Saedi HFS, Ashoor JA, Rasool MI, Hasan SA, ALtrufi MH. Topical Astaxanthin Attenuates Imiquimod-Induced Psoriasiform Dermatitis by Downregulating Psoriasis-Associated Keratin Gene Expression (Krt16, Krt17, Krt6a) and Inhibiting the JAK-STAT Signaling Pathway. Molecules. 2026. doi:10.3390/molecules31071191

BibTeX
@article{Albahadly2026,
  author = {Albahadly, Waleed Khaled Younis and Al-Saedi, Haider Falih Shamikh and Ashoor, Jamal Ali and Rasool, Mohammed Ibrahim and Hasan, Samer Ali and ALtrufi, Meeqaat H},
  title = {Topical Astaxanthin Attenuates Imiquimod-Induced Psoriasiform Dermatitis by Downregulating Psoriasis-Associated Keratin Gene Expression (Krt16, Krt17, Krt6a) and Inhibiting the JAK-STAT Signaling Pathway},
  journal = {Molecules},
  year = {2026},
  doi = {10.3390/molecules31071191}
}
Kostenlos starten →